logo-loader
viewIXICO PLC

IXICO lands three new clinical trial contracts, reflecting its growing expertise in Alzheimer's disease

The group will carry out work on a phase I study, it has also signed an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial

IXICO PLC -

IXICO PLC (LON:IXI), the data analytics specialist focused on neuroscience, said it has landed three new contracts in the area of Alzheimer's disease.

The group will carry out work on a phase I study, it has also signed an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial

IXICO said the new business builds on its expertise in the field of Alzheimer's and pointed out that it was in addition to the partnership with the Global Alzheimer's Platform announced in September.

In a statement, the company’s chief commercial officer, Lammert Albers, noted: "Today there are 50 million people worldwide that suffer with Alzheimer's and other forms of dementias.

“There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of Alzheimer's disease. With more than 120 unique investigational drugs in clinical trials, IXICO is proud to support some of these potential treatments that one day may be in the hands of Alzheimer's patients worldwide."

Quick facts: IXICO PLC

Price: 117.5 GBX

AIM:IXI
Market: AIM
Market Cap: £55.33 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IXICO signs contract to provide neuroimaging services for clinical trial for...

IXICO PlC (AIM: IXI) Chief Commercial Officer, Lammert Albers joined Steve Darling from Proactive with news the company is to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease. Albers telling Proactive "these services will enable clients to...

14 hours, 46 minutes ago

2 min read